Loading
Life sciences · Journal article
Frontiers in Bacteriology · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The convergence of artificial intelligence (AI) and antimicrobial pharmacology is creating unprecedented opportunities to accelerate antimicrobial discovery, optimize therapeutic strategies, and reduce the global burden of infectious diseases. A critical determinant of the successful integration of AI into antimicrobial pharmacology is the accurate and interpretable prediction of pharmacokinetic (PK) and pharmacodynamic (PD) properties, including measures such as the minimum inhibitory concentration (MIC), to identify the PK/PD indices and dosing regimens that maximize antimicrobial efficacy while ensuring safety. We review recent developments in AI models for antimicrobial PK/PD and critically examine their performance, interpretability, generalizability, and readiness for clinical translation. We provide a practical framework to help researchers, microbiologists, pharmacologists, and clinicians evaluate the strengths, limitations, and appropriate applications of these emerging approaches. We anticipate that rigorous development, transparent validation, and thoughtful implementation of AI-driven PK/PD models will accelerate antimicrobial discovery, optimize precision dosing, and ultimately improve patient outcomes.